Clinical trials: Ustekinumab
Psoriasis
BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of risankizumab (BI 655066) to support registration for…
- Trial name
- NCT02684357
- Testing
- risankizumab, ustekinumab
- Volunteers
- 577 people
- Sponsor
- AbbVie
Psoriasis
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT04673786
- Testing
- CT-P43, Stelara
- Where
- Estonia
- Volunteers
- 509 people
- Sponsor
- Celltrion
Psoriasis
An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
The purpose of this study is to evaluate the efficacy and safety of ustekinumab in pediatric participants aged greater than or equal to (>=) 6 through less than (<) 12 years with moderate to severe chronic plaque psoriasis
- Trial name
- CADMUS Jr (NCT02698475)
- Testing
- Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Polymyositis, Dermatomyositis
A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or…
- Trial name
- NCT03981744
- Testing
- Ustekinumab 6 mg/kg, Ustekinumab 90 mg
- Where
- 32 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Janssen Pharmaceutical K.K.
Nonradiographic Axial Spondylitis, Ankylosing
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
The purpose of this study is to assess the efficacy and safety of ustekinumab in adult participants with active nonradiographic axial spondyloarthritis (nr-AxSpA) measured by the reduction in signs and symptoms of nonradiographic…
- Trial name
- NCT02407223
- Testing
- Group 2: Ustekinumab 45 mg, Group 3: Ustekinumab 90 mg
- Where
- 90 sites in Argentina, Australia and 12 more
- Volunteers
- 356 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Plaque Psoriasis
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
- Trial name
- CLARITY (NCT02826603)
- Testing
- Secukinumab, Ustekinumab
- Where
- 154 sites in United States, Canada and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy, safety, and immunogenicity of ABP 654 compared with ustekinumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04607980
- Testing
- ABP 654, Ustekinumab
- Where
- 84 sites in United States, Canada and 6 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Plaque Psoriasis, Psoriasis Vulgaris
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
The trial investigates the efficacy and safety of brodalumab against guselkumab in treatment for patients with moderate-to-severe plaque psoriasis who still have some remaining symptoms after ustekinumab treatment.
- Conditions
- Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
- Trial name
- COBRA (NCT04533737)
- Testing
- Brodalumab, Guselkumab
- Where
- 65 sites in Austria, Belgium and 10 more
- Volunteers
- 113 people
- Sponsor
- LEO Pharma
Psoriasis
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to assess the effect of extending maintenance dosing intervals beyond 12 weeks on the clinical efficacy and safety of ustekinumab in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- PSTELLAR (NCT01550744)
- Testing
- Ustekinumab 45 mg, Ustekinumab 90 mg
- Where
- 40 sites in United States
- Volunteers
- 478 people
- Sponsor
- Janssen Biotech, Inc.
Crohn's Disease, Colitis
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
The primary purpose of this study is to evaluate the efficacy and safety of 2 maintenance regimens of ustekinumab administered subcutaneously to patients with moderately to severely active Crohn's disease who responded to…
- Conditions
- Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease
- Trial name
- NCT01369355
- Testing
- Ustekinumab 90 mg SC q8w, Ustekinumab 130 mg IV, Ustekinumab 90 mg SC q12w
- Where
- 220 sites in United States, Australia and 24 more
- Volunteers
- 1,282 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease, Inflammatory Bowel Disease
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, IBD, Colitis
- Trial name
- NCT01369342
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 220 sites in United States, Australia and 20 more
- Volunteers
- 640 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
The purpose of this study is to compare the efficacy of treatment with ustekinumab or adalimumab in biologic naive participants with moderately-to-severely active Crohn's disease (CD) who have previously failed or were intolerant…
- Trial name
- SEAVUE (NCT03464136)
- Testing
- Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
- Where
- 182 sites in United States, Australia and 16 more
- Volunteers
- 386 people
- Sponsor
- Janssen Scientific Affairs, LLC
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Psoriasis
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate…
- Trial name
- NCT04761627
- Testing
- Ustekinumab, ABP 654
- Where
- 88 sites in United States, Canada and 6 more
- Volunteers
- 494 people
- Sponsor
- Amgen
Psoriatic Arthritis
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
- Trial name
- NCT00267956
- Testing
- CNTO 1275 63 mg
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 146 people
- Sponsor
- Centocor, Inc.
Crohn Disease
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
- Trial name
- NCT00265122
- Testing
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.
Lupus Erythematosus, Systemic
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in…
- Trial name
- NCT02349061
- Testing
- Ustekinumab IV, Ustekinumab SC, Concomitant Medication
- Where
- 43 sites in United States, Argentina and 7 more
- Volunteers
- 102 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
- Trial name
- NCT00747344
- Testing
- Ustekinumab 45 mg - CP, Ustekinumab 45 mg - after CP
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 121 people
- Sponsor
- Centocor, Inc.